Samsung Bioepis Obodence Shows Comparable Efficacy Across 456-Patient Population
Prolia Biosimilar's Phase 3 Results Reconfirmed
Comparable Efficacy Demonstrated Regardless of Age, BMI, and Other Variables
Obodence (project name SB16), Samsung Bioepis's osteoporosis treatment, has demonstrated therapeutic effects similar to those of the original drug across a variety of patient groups.
Samsung Bioepis announced on the 18th that it presented the results of a follow-up subgroup analysis from the Phase 3 clinical trial of Obodence at the international osteoporosis conference (WCO-IOF-ESCEO) held in Prague, Czech Republic from April 16 to 19.
This study was based on global Phase 3 clinical data involving 456 postmenopausal women with osteoporosis, evaluating how patient characteristics such as age, body mass index (BMI), and history of vertebral fracture affect drug efficacy.
The analysis assessed the rate of change in bone mineral density in the lumbar spine, hip, and femoral neck at 12 months after administration. The results showed that, regardless of demographic or disease characteristics, Obodence demonstrated therapeutic effects comparable to those of the original drug.
The company explained that these findings reconfirm the biological equivalence observed in the Phase 3 trial across various patient populations.
Donghoon Shin, Executive Vice President of Samsung Bioepis, said, "Through these study results, we have once again demonstrated the consistent therapeutic effects of Obodence across a wide range of patient groups in real-world prescribing environments. Moving forward, we will continue to strengthen our research and development capabilities to further expand the prescription of high-quality biopharmaceuticals based on scientific evidence."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Obodence is a biosimilar of Prolia, developed by Samsung Bioepis. In Korea, it is co-marketed with Hanmi Pharmaceutical. The company is also expanding its supply in the United States and Europe.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.